Amgen, headquartered in Thousand Oaks, California, is a biotechnology company employing 26,700 staff, focusing on developing human therapeutics for high unmet medical needs. Its product portfolio includes Aranesp, ENBREL, and Prolia, among others.
AMGN has been in the news recently: Amgen Inc (AMGN) shares dropped 5.7% to $272.88 following the release of mixed phase two study results for its obesity treatment, MariTide. The competitive landscape in the weight loss drug market is intensifying, as Eli Lilly's orforglipron demonstrated a 7.6% weight loss in Type 2 diabetes patients.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
